Survival benefits of dose-dense early postoperative intraperitoneal chemotherapy in front-line therapy for advanced ovarian cancer: a randomised controlled study-Reference-Cited by-同舟云学术

Survival benefits of dose-dense early postoperative intraperitoneal chemotherapy in front-line therapy for advanced ovarian cancer: a randomised controlled study

Published:2019-08 Issue:5 Volume:121 Page:425-428
ISSN:0007-0920
Container-title:British Journal of Cancer
language:en
Short-container-title:Br J Cancer

Author:

Shi Tingyan, ,Jiang Rong,Pu Hong,Yang Huijuan,Tu Dongsheng,Dai Zhiyuan,Cai Yunlang,Zhang Yuqin,Cheng Xi,Jia Huixun,Tu Ruiqin,Wang Huaying,Tang Jie,Luan Yuting,Cai Shumo,Zang Rongyu^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://www.nature.com/articles/s41416-019-0543-1.pdf

Reference14 articles.

1. Alberts, D. S., Liu, P. Y., Hannigan, E. V., O’Toole, R., Williams, S. D., Young, J. A. et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N. Engl. J. Med. 335, 1950–1955 (1996).

2. Armstrong, D. K., Bundy, B., Wenzel, L., Huang, H. Q., Baergen, R., Lele, S. et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N. Engl. J. Med. 354, 34–43 (2006).

3. Markman, M., Bundy, B. N., Alberts, D. S., Fowler, J. M., Clark-Pearson, D. L., Carson, L. F. et al. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J. Clin. Oncol. 19, 1001–1007 (2001).

4. Walker, J. L., Brady, M. F., Wenzel, L., Fleming, G. F., Huang, H. Q., DiSilvestro, P. A. et al. Randomized trial of intravenous versus intraperitoneal chemotherapy plus bevacizumab in advanced ovarian carcinoma: an NRG Oncology/Gynecologic Oncology Group Study. J. Clin. Oncol. JCO1801568. https://doi.org/10.1200/JCO.18.01568 (2019).

5. Shi, T., Jiang, R., Yu, J., Yang, H., Tu, D., Dai, Z. et al. Addition of intraperitoneal cisplatin and etoposide to first-line chemotherapy for advanced ovarian cancer: a randomised, phase 2 trial. Br. J. Cancer 119, 12–18 (2018).

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical guidelines for ovarian cancer: the Korean Society of Gynecologic Oncology guidelines;Journal of Gynecologic Oncology;2024

2. Cytoreductive Surgery plus Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in patients with Advanced Ovarian Cancer: A 2-year survival analysis study;Current Women s Health Reviews;2023-08-22

3. Who really benefits from intraperitoneal chemotherapy for advanced ovarian cancer? A treatment‐free survival analysis of the AICE trial;BJOG: An International Journal of Obstetrics & Gynaecology;2022-11

4. mPEG-PDLLA Micelles Potentiate Docetaxel for Intraperitoneal Chemotherapy in Ovarian Cancer Peritoneal Metastasis;Frontiers in Pharmacology;2022-04-06

5. Efficacy of conversion surgery after a single intraperitoneal administration of paclitaxel and systemic chemotherapy for gastric cancer with peritoneal metastasis;Langenbeck's Archives of Surgery;2022-01-05